Novo Nordisk's Victoza is the latest GLP-1 analog to be approaching the market for the treatment of type 2 diabetes. See previous posts on GLP-1 rivals Amylin/Lilly, Roche, and GSK.
In this trial, Victoza will be studied for its cardiovascular safety in treatment of type 2 diabetics, since there is a well established link between cvs disaease and type 2 diabetes. This trial will attempt to show that use of Victoza will lead to better cvs outcomes in these patients corroborating a prvious study of Victoza (liraglutide).
Posted by Bruce Lehr May 7th 2010.
Comments